| ATPC 0.1125 60.71% | MTEN 0.032 -9.35% | OCG 0.0101 -14.41% | SOXS 2.105 -7.68% | AUID 1.8301 84.39% | CJMB 3.3967 203.28% | IVP 0.0532 -35.12% | ZSL 2.87 1.95% | NVDA 188.6 2.98% | SLV 84.07 -0.58% | ASST 0.9832 -4.54% | INTC 48.835 0.24% | SPHL 15.395 584.22% | DVLT 0.7302 1.67% | BBAI 6.45 3.04% | TZA 5.935 -3.65% | GRAB 4.355 -5.94% | TQQQ 54.815 1.83% | BYND 1.045 8.64% | BNKK 4.2269 52.05% | SOXL 59.9614 8.27% | ONDS 13.51 -0.37% | APLT 0.1009 1.00% | IBRX 3.8945 28.96% | NVD 6.9723 -5.91% | DNN 3.565 2.15% | BITO 13.245 -2.32% | DUST 5.72 -1.29% | AAL 15.685 3.60% | PLUG 2.31 -1.70% | TSLS 5.175 -0.29% | TSLL 18.1599 0.50% | PTHL 0.962 118.74% | EEM 58.18 0.74% | SPY 693.39 0.44% | MSTX 4.88 -6.15% | FNGD 5.465 -0.82% | SIDU 3.78 0.80% | AMD 233.32 4.35% | IBIT 54.14 -2.34% | NOK 6.6358 4.34% | ACHR 9.0999 2.13% | JDST 2.069 -1.71% | RZLV 4.715 16.13% | QQQ 623.35 0.61% | GPUS 0.2905 -9.47% | XLE 47.6476 -0.86% | TSLA 440.4 0.27% | VALE 14.735 0.86% | SNAP 7.775 -1.58%

JPMorgan Upgrades Kodiak Sciences To Neutral, Sees Catalyst-Heavy Period Ahead

JPMorgan upgraded Kodiak Sciences (NASDAQ:KOD) from Underweight to Neutral and set a December 2026 price target of $15.00.

The bank said Kodiak is entering a catalyst-rich period over the next two years, with pivotal trial data expected for tarcocimab, KSI-501, and KSI-101. While acknowledging that valuation is not a barrier to a more positive stance, JPMorgan noted that investor sentiment remains mixed and that clear clinical wins may be required to shift views more favorably.

The firm sees Kodiak shares performing in line with the broader biotech sector until further clarity emerges from these upcoming data releases.

Published on: August 14, 2025